Attila Feher1, Ajay Srivastava2, Michael A Quail3, Nabil E Boutagy1, Pravien Khanna4, Lynn Wilson1, Edward J Miller5, Yi-Hwa Liu1, Forrester Lee1, Albert J Sinusas6. 1. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut. 2. Division of Cardiovascular Medicine, Scripps Clinic, La Jolla, California. 3. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; Institute of Cardiovascular Science, University College London, London, United Kingdom. 4. Rutgers-Robert Wood Johnson University Hospital, New Brunswick, New Jersey. 5. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut. 6. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut. Electronic address: albert.sinusas@yale.edu.
Abstract
OBJECTIVES: This study aimed to evaluate the long-term prognostic value of serial assessment of coronary flow reserve (CFR) by rubidium Rb 82 (82Rb) positron emission tomography (PET) in heart transplantation (HT) patients. BACKGROUND: Cardiac allograft vasculopathy is a major determinant of late mortality in HT recipients. The long-term prognostic value of serial CFR quantification by PET imaging in HT patients is unknown. METHODS: A total of 89 patients with history of HT (71% men, 7.0 ± 5.7 years post-HT, age 57 ± 11 years) scheduled for dynamic rest and stress (dipyridamole) 82Rb PET between March 1, 2008 and July 31, 2009 (PET-1) were prospectively enrolled in a single-center study. PET myocardial perfusion studies were reprocessed using U.S. Food and Drug Administration-approved software (Corridor 4DM, version 2017) for calculation of CFR. Follow-up PET (PET-2) imaging was performed in 69 patients at 1.9 ± 0.3 years following PET-1. Patients were categorized based on CFR values considering CFR ≤1.5 as low and CFR >1.5 as high CFR. RESULTS: Forty deaths occurred during the median follow-up time of 8.6 years. Low CFR at PET-1 was associated with a 2.77-fold increase in all-cause mortality (95% confidence interval [CI]: 1.34 to 5.74; p = 0.004). CFR decreased over time in patients with follow-up imaging (PET-1: 2.11 ± 0.74 vs. PET-2: 1.81 ± 0.61; p = 0.003). Twenty-five patients were reclassified based on PET-1 and PET-2 (high to low CFR: n = 18, low to high CFR: n = 7). Overall survival was similar in patients reclassified from high to low as patients with low to low CFR, whereas patients reclassified from low to high had similar survival as patients with high to high CFR. In multivariate Cox regression of patients with PET-2, higher baseline CFR (hazard ratio [HR] for a 0.73 unit (one SD) increase: 0.36, 95% CI: 0.16 to 0.82) and reduction in CFR from PET-1 to PET-2 (HR for a 0.79 unit (one SD) decrease: 1.50 to 7.84) were independent predictors of all-cause mortality. CONCLUSIONS: Serial assessment of CFR by 82Rb PET independently predicts long-term mortality in HT patients.
OBJECTIVES: This study aimed to evaluate the long-term prognostic value of serial assessment of coronary flow reserve (CFR) by rubidium Rb 82 (82Rb) positron emission tomography (PET) in heart transplantation (HT) patients. BACKGROUND:Cardiac allograft vasculopathy is a major determinant of late mortality in HT recipients. The long-term prognostic value of serial CFR quantification by PET imaging in HTpatients is unknown. METHODS: A total of 89 patients with history of HT (71% men, 7.0 ± 5.7 years post-HT, age 57 ± 11 years) scheduled for dynamic rest and stress (dipyridamole) 82Rb PET between March 1, 2008 and July 31, 2009 (PET-1) were prospectively enrolled in a single-center study. PET myocardial perfusion studies were reprocessed using U.S. Food and Drug Administration-approved software (Corridor 4DM, version 2017) for calculation of CFR. Follow-up PET (PET-2) imaging was performed in 69 patients at 1.9 ± 0.3 years following PET-1. Patients were categorized based on CFR values considering CFR ≤1.5 as low and CFR >1.5 as high CFR. RESULTS: Forty deaths occurred during the median follow-up time of 8.6 years. Low CFR at PET-1 was associated with a 2.77-fold increase in all-cause mortality (95% confidence interval [CI]: 1.34 to 5.74; p = 0.004). CFR decreased over time in patients with follow-up imaging (PET-1: 2.11 ± 0.74 vs. PET-2: 1.81 ± 0.61; p = 0.003). Twenty-five patients were reclassified based on PET-1 and PET-2 (high to low CFR: n = 18, low to high CFR: n = 7). Overall survival was similar in patients reclassified from high to low as patients with low to low CFR, whereas patients reclassified from low to high had similar survival as patients with high to high CFR. In multivariate Cox regression of patients with PET-2, higher baseline CFR (hazard ratio [HR] for a 0.73 unit (one SD) increase: 0.36, 95% CI: 0.16 to 0.82) and reduction in CFR from PET-1 to PET-2 (HR for a 0.79 unit (one SD) decrease: 1.50 to 7.84) were independent predictors of all-cause mortality. CONCLUSIONS: Serial assessment of CFR by 82Rb PET independently predicts long-term mortality in HTpatients.
Authors: Lærke Marie Nelson; Thomas Emil Christensen; Kasper Rossing; Philip Hasbak; Finn Gustafsson Journal: J Nucl Cardiol Date: 2021-08-19 Impact factor: 3.872
Authors: Annagrazia Cecere; Peter L M Kerkhof; Giovanni Civieri; Annalisa Angelini; Antonio Gambino; Angela Fraiese; Tomaso Bottio; Elena Osto; Giulia Famoso; Marny Fedrigo; Enrico Giacomin; Giuseppe Toscano; Roberta Montisci; Sabino Iliceto; Gino Gerosa; Francesco Tona Journal: Front Cardiovasc Med Date: 2022-06-24
Authors: Sharon Chih; Aun Yeong Chong; Jordan Bernick; George A Wells; Robert A deKemp; Ross A Davies; Ellamae Stadnick; Derek Y So; Christopher Overgaard; Lisa M Mielniczuk; Rob S B Beanlands Journal: J Nucl Cardiol Date: 2020-01-28 Impact factor: 5.952
Authors: Jack Aguilar; Robert J H Miller; Yuka Otaki; Balaji Tamarappoo; Sean Hayes; John Friedman; Piotr J Slomka; Louise E J Thomson; Michelle Kittleson; Jignesh K Patel; Jon A Kobashigawa; Daniel S Berman Journal: Transplantation Date: 2022-03-01 Impact factor: 5.385
Authors: Mihir A Kelshiker; Henry Seligman; James P Howard; Haseeb Rahman; Michael Foley; Alexandra N Nowbar; Christopher A Rajkumar; Matthew J Shun-Shin; Yousif Ahmad; Sayan Sen; Rasha Al-Lamee; Ricardo Petraco Journal: Eur Heart J Date: 2022-04-19 Impact factor: 35.855
Authors: Uttam M Shrestha; Maria Sciammarella; Miguel Hernandez Pampaloni; Elias H Botvinick; Grant T Gullberg; Teresa DeMarco; Youngho Seo Journal: Int J Cardiovasc Imaging Date: 2020-10-29 Impact factor: 2.357